name:-0.014195919036865
name:-0.02328896522522
name:-0.0069961547851562
BIOPROJET Patent Filings

BIOPROJET

Patent Applications and Registrations

Patent applications and USPTO patent grants for BIOPROJET.The latest application filed is for "benzimidazole derivatives as dual histamine h1 and histamine h4 receptor ligands".

Company Profile
5.26.15
  • BIOPROJET - Paris FR
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks
Patent Activity
PatentDate
Benzimidazole Derivatives As Dual Histamine H1 And Histamine H4 Receptor Ligands
App 20220281839 - BERREBI-BERTRAND; Isabelle ;   et al.
2022-09-08
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
Grant 11,306,069 - Berrebi-Bertrand , et al. April 19, 2
2022-04-19
Novel Combinations Of A H3 Antagonist And A Noradrenaline Reuptake Inhibitor, And The Therapeutical Uses Thereof
App 20220079932 - LIGNEAU; Xavier ;   et al.
2022-03-17
Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof
Grant 11,229,632 - Ligneau , et al. January 25, 2
2022-01-25
Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same
Grant 11,078,183 - Capet , et al. August 3, 2
2021-08-03
Combination of adrenalin with an antidepressant for use in the treatment of shocks
Grant 10,952,987 - Schwartz , et al. March 23, 2
2021-03-23
Novel Combinations Of A H3 Antagonist And A Noradrenaline Reuptake Inhibitor, And The Therapeutical Uses Thereof
App 20200030310 - LIGNEAU; Xavier ;   et al.
2020-01-30
Benzimidazole Derivatives As Dual Histamine H1 And Histamine H4 Receptor Ligands
App 20190144421 - BERREBI-BERTRAND; Isabelle ;   et al.
2019-05-16
Combination Of Adrenalin With An Antidepressant For Use In The Treatment Of Shocks
App 20190117614 - SCHWARTZ; Jean-Charles ;   et al.
2019-04-25
Form of administration of enkephalinase inhibitor
Grant 9,439,853 - Julien , et al. September 13, 2
2016-09-13
Piperidinyl monocarboxylic acids as S1P1 receptor agonists
Grant 9,266,867 - Capet , et al. February 23, 2
2016-02-23
6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
Grant 9,255,101 - Berrebi-Bertrand , et al. February 9, 2
2016-02-09
A Combination of Adrenaline with an Antidepressant for Use in the Treatment of Shocks
App 20150306065 - SCHWARTZ; Jean-Charles ;   et al.
2015-10-29
Benzazole derivatives as histamine H4 receptor ligands
Grant 9,029,357 - Berrebi-Bertrand , et al. May 12, 2
2015-05-12
Benzazole Derivatives as Histamine H4 Receptor Ligands
App 20150004181 - BERREBI-BERTRAND; Isabelle ;   et al.
2015-01-01
Dicarboxylic acid derivatives as S1P1 receptor agonists
Grant 8,809,539 - Capet , et al. August 19, 2
2014-08-19
Carbonylated (aza) cyclohexanes as dopamine D.sub.3 receptor ligands
Grant 8,802,678 - Capet , et al. August 12, 2
2014-08-12
Form of Administration of Enkephalinase Inhibitor
App 20130331423 - Julien; Jean-Stephane ;   et al.
2013-12-12
Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications
App 20130324507 - BERREBI-BERTRAND; Isabelle ;   et al.
2013-12-05
New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
App 20130324506 - BERREBI-BERTRAND; Isabelle ;   et al.
2013-12-05
Benzazole Derivatives as Histamine H4 Receptor Ligands
App 20130231329 - Berrebi-Bertrand; Isabelle ;   et al.
2013-09-05
Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H.sub.3-receptor ligands
Grant 8,486,947 - Schwartz , et al. July 16, 2
2013-07-16
Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Grant 8,354,430 - Raga , et al. January 15, 2
2013-01-15
Form of administration of racecadotril
Grant 8,318,203 - Schwartz , et al. November 27, 2
2012-11-27
Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Grant 8,207,197 - Raga , et al. June 26, 2
2012-06-26
Novel Pharmaceutically Acceptable Salts Of 4-(1h-imidazol-4-ylmethyl)pyridine And Their Therapeutical Uses
App 20120129892 - Capet; Marc ;   et al.
2012-05-24
Combination product comprising an antagonist or inverse agonist of histamine receptor H.sub.3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs
Grant 8,106,041 - Schwartz , et al. January 31, 2
2012-01-31
Histamine H3-receptor ligands and their therapeutic applications
Grant 8,076,329 - Bertrand , et al. December 13, 2
2011-12-13
Histamine H.sub.3-receptor ligands and their therapeutic application
Grant 8,017,646 - Bertrand , et al. September 13, 2
2011-09-13
Combination Of Modafinil And An Antagonist Or Inverse Agonist Of The H3 Receptor
App 20090312367 - Schwartz; Jean-Charles ;   et al.
2009-12-17
Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents
Grant 7,432,269 - Capet , et al. October 7, 2
2008-10-07
Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands
App 20080214542 - Capet; Marc ;   et al.
2008-09-04
Formulation
Grant 6,919,093 - Lecomte , et al. July 19, 2
2005-07-19
LTA4 hydrolase inhibitors
Grant 6,878,723 - Danvy , et al. April 12, 2
2005-04-12
Process for synthesizing N-(mercaptoacyl) amino acid derivatives from alpha-substituted acrylic acids
Grant 6,835,851 - Monteil , et al. December 28, 2
2004-12-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed